 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Context Therapeutics (CNTX) has provided an update. Context Therapeutics Inc. has announced the submission of an IND application to the FDA for a P...

Context Therapeutics Advances Cancer Trial with FDA Submission

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Context Therapeutics submits IND application for CTIM-76

Important Regulatory Milestone Supports Next Phase of CTIM-76 DevelopmentPHILADELPHIA, April 01, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ( Context or the Company ) (Nasdaq: CNTX), a...

Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers

Context Therapeutics (NASDAQ:CNTX  Free Report) had its target price lowered by HC Wainwright from $5.00 to $4.00 in a research report sent to investors on Thursday, Benzinga reports. HC...

Context Therapeutics (NASDAQ:CNTX) Price Target Cut to $4.00

Maxim Group analyst Jason McCarthy maintained a Buy rating on Context Therapeutics (CNTX Research Report) yesterday and set a price target of $4...

Buy Rating Justified by Advances in T Cell Engagers and Context Therapeutics' Strategic Drug Positioning

Context Therapeutics expects cash to fund operations into late 2024

Context Therapeutics reports 2023 EPS ($1.50) vs. (93c) last year

CTIM-76 IND filing on track for late March 2024 Cash and cash equivalents of $14.4 million as of December 31, 2023 Company expects its cash and cash equivalents will continue to fund operations...

Context Therapeutics Reports Full Year 2023 Operating and Financial Results

Theres a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Context Therapeutics (CNTX Research Report) and Barinthus Biotherapeutics...

Wall Street Analysts Are Bullish on Top Healthcare Picks

Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is dedicated to improving the lives of women living with cancer. It engages in developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The firm's robust clinical program for candidate onapristone extended release (ONA-XR) comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. Its ONA-XR is a novel, first-in-class small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women?s cancers. The company was founded by Martin Lehr and Felix Kim in April 2015 and is headquartered in Philadelphia, PA.

Volume (M)	4,492.00
52-Wk High	$1.69
52-Wk Low	$0.47

CNTX Context Therapeutics Inc

About

Feed

News

Fundamentals